Howard Doran - Renalytix Chief Officer
| RNLX Stock | USD 0.39 0.05 11.36% |
Executive
Howard Doran is Chief Officer of Renalytix AI
| Age | 63 |
| Address | 1460 Broadway, New York, NY, United States, 10036 |
| Phone | 646 397 3970 |
| Web | https://renalytix.com |
Renalytix Management Efficiency
The company has return on total asset (ROA) of (0.8832) % which means that it has lost $0.8832 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.514) %, meaning that it created substantial loss on money invested by shareholders. Renalytix's management efficiency ratios could be used to measure how well Renalytix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -1.71 in 2024. Return On Capital Employed is likely to rise to -1.78 in 2024. At this time, Renalytix's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 18 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 7.6 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kyle Salyers | Health Catalyst | N/A | |
| Benjamin Stilwill | Streamline Health Solutions | 34 | |
| Michael McQuigg | HealthStream | 56 | |
| Tarah Bryan | Health Catalyst | N/A | |
| Lance Seach | Streamline Health Solutions | N/A | |
| Benjamin Landry | Health Catalyst | N/A | |
| Megan Charko | National Research Corp | N/A | |
| Jacqueline JD | Akili Inc | 65 | |
| Bryant Reeves | Streamline Health Solutions | N/A | |
| Linda Llewelyn | Health Catalyst | 57 | |
| Richard Putnam | HealthEquity | N/A | |
| Rebecca Adams | Forian Inc | N/A | |
| Steve Lindsay | HealthEquity | N/A | |
| Kevin Freeman | Health Catalyst | 51 | |
| Paul Reuscher | Forian Inc | N/A | |
| Arthur Newman | HealthStream | 75 | |
| Scott Fenstermacher | HealthStream | 55 | |
| Kevin Scharnhorst | Health Catalyst | N/A | |
| Holly Rimmasch | Health Catalyst | N/A | |
| Adam Brown | Health Catalyst | N/A | |
| Ryan Barry | Health Catalyst | N/A | |
Management Performance
| Return On Equity | -6.51 | ||||
| Return On Asset | -0.88 |
Renalytix AI Leadership Team
Elected by the shareholders, the Renalytix's board of directors comprises two types of representatives: Renalytix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Renalytix. The board's role is to monitor Renalytix's management team and ensure that shareholders' interests are well served. Renalytix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Renalytix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Oliver III, Chief Officer | ||
| Jean Casner, VP Officer | ||
| Baljit Singh, Head Operations | ||
| Howard Doran, Chief Officer | ||
| Salim FCA, Company Secretary | ||
| Fergus Fleming, Chief Officer | ||
| Andria ParksHerrera, VP Marketing | ||
| James MBA, Chief Officer |
Renalytix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Renalytix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.51 | ||||
| Return On Asset | -0.88 | ||||
| Operating Margin | (11.76) % | ||||
| Current Valuation | 59.53 M | ||||
| Shares Outstanding | 73.77 M | ||||
| Shares Owned By Insiders | 4.85 % | ||||
| Shares Owned By Institutions | 5.52 % | ||||
| Number Of Shares Shorted | 627.4 K | ||||
| Price To Book | 20.68 X | ||||
| Price To Sales | 22.89 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Renalytix AI offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Renalytix's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Renalytix Ai Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Renalytix Ai Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renalytix AI. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Renalytix Stock analysis
When running Renalytix's price analysis, check to measure Renalytix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Renalytix is operating at the current time. Most of Renalytix's value examination focuses on studying past and present price action to predict the probability of Renalytix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Renalytix's price. Additionally, you may evaluate how the addition of Renalytix to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Renalytix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Renalytix. If investors know Renalytix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Renalytix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.76) | Revenue Per Share 0.052 | Quarterly Revenue Growth (0.41) | Return On Assets (0.88) | Return On Equity (6.51) |
The market value of Renalytix AI is measured differently than its book value, which is the value of Renalytix that is recorded on the company's balance sheet. Investors also form their own opinion of Renalytix's value that differs from its market value or its book value, called intrinsic value, which is Renalytix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renalytix's market value can be influenced by many factors that don't directly affect Renalytix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Renalytix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Renalytix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renalytix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.